De­ter­mined to build the lead­ing biotech play­er in a new R&D space, Steven Holtz­man lines up $55M for the next stage at Deci­bel

There are no big phar­mas or large cap biotechs build­ing a pipeline of drugs for hear­ing loss. So Steven Holtz­man wants to build a lead­ing play­er in the field from scratch. And now he and the team at Deci­bel have an ex­tra $55 mil­lion of cash to take the next step or two in that jour­ney.

This new round brings the Deci­bel CEO’s cash re­serves to more than $100 mil­lion at the Boston-based biotech, fund­ing plans to grow the staff from 65 to 100 or more as Holtz­man con­tin­ues his mis­sion to build out “the world’s first ful­ly in­te­grat­ed” hear­ing drug dis­cov­ery and de­vel­op­ment plat­form.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER